Triamcinolone acetonide-Ketorolac-Ropivacaine

Phase 3Small molecule

Triamcinolone acetonide-Ketorolac-Ropivacaine is one of 4 small molecule programs targeting Ketorolac. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KetorolacRecruiting

KetorolacPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Ketorolac

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Approved

2 2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 3

Toradol

JJavelin Pharmaceuticals

Phase 3

18 4

Triamcinolone acetonide-Ketorolac-Ropivacaine

UUnited Health Services Hospitals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ketorolac1 trial

Triamcinolone Ketorolac (TriKe) Knee Trial

Recruiting·UUnited Health Services Hospitals, Inc.·Phase 4·NCT05336968·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Triamcinolone acetonide-Ketorolac-Ropivacaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triamcinolone acetonide-Ketorolac-Ropivacaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triamcinolone acetonide-Ketorolac-Ropivacaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — United Health Services Hospitals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUnited Health Services Hospitals, Inc.

Triamcinolone acetonide-Ketorolac-Ropivacaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ketorolac1 trial

References

Drug Info

Quick Facts

Related News